Digestive health

What Cologuard Is Looking For in the Stool

Save

Mailed to a lab in a prepaid box, done at home with no bowel-prep laxative, Cologuard tests a single stool sample for altered DNA and hidden hemoglobin at once. The current version was validated in a large national trial and ranks as a second-tier screening option behind colonoscopy and annual FIT. Here is what the test is mechanically doing, and what a result should — and should not — mean to you.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Continue in Claude

Open a chat with this article’s link already in the message, and keep asking questions there. Claude reads the article and its sources; nothing about you is included.

Continue in Claude →

The button opens the Claude desktop app and fills in the message for you to review before sending. No desktop app, or reading on a phone? Copy the prompt and paste it into any AI.

What Cologuard Actually Tests For

Cologuard combines two separate signals from a single stool sample into one lab result. One channel looks for altered DNA — genetic and epigenetic changes that colon cells shed into stool as they turn toward a polyp or cancer. The other is a fecal immunochemical test for hemoglobin, present at concentrations far below what a person could see. A lab algorithm folds both readings into a single positive or negative call 1.

Either signal by itself can produce a positive result, which is what separates this test from a plain fecal immunochemical test that only checks for blood. The multitarget approach used today was validated in a large national trial, the study behind the current version of Cologuard, which reported the test's sensitivity for colorectal cancer and its specificity in an average-risk screening population 1. The original version of the test, cleared by the FDA in 2014, showed the same basic trade-off: multitarget stool DNA testing caught more cancers on a single round than FIT alone, but it also flagged more people who turned out not to have one 2.

Collecting and Mailing the Sample

The kit arrives by mail and is designed for home use, with no bowel-prep laxative, no special diet, and no clinic visit required. A whole bowel movement is captured in the provided container, a small amount transfers to a preservative vial, and the sealed kit ships back to the lab in a prepaid box — the entire process is built to happen without a person leaving their bathroom.

What the lab does with it afterward is unglamorous by design. The sample is tested for the DNA and blood markers described above, and the algorithm reports one combined result back to the ordering clinician rather than a list of individual marker values a patient would have to interpret alone. Following the kit's own instructions on sample size and mailing time matters more than anything else in this part of the process.

What a Positive or Negative Result Actually Means

A negative result means neither the DNA markers nor the blood signal crossed the test's threshold — not that the colon is free of concern, only that this test found nothing to flag. A positive result means one or both signals crossed the threshold, and it functions as a screening flag rather than a diagnosis. Cologuard cannot say what caused a positive — a polyp, an early cancer, or something else. Only a colonoscopy can look directly and remove what it finds.

That is why a positive result routes to one specific next step rather than a menu of choices. cologuard vs colonoscopy is worth reading before testing, not after a positive result arrives, because it explains what the follow-up procedure involves and why it is the only test in this pathway that can both see and treat in the same visit — a biopsy taken during that same colonoscopy, not a separate appointment weeks later, is usually what turns a flag into an answer.

Where Cologuard Sits Among Screening Options

Cologuard is not the first-choice test in most guideline rankings; it is generally treated as a second-tier option. The U.S. Multi-Society Task Force on Colorectal Cancer ranks colonoscopy every ten years and annual FIT as first-tier screening choices, placing the stool DNA test and CT colonography in a second tier 3. That ranking reflects test performance and practical trade-offs, not which test is easiest to complete.

The distinction matters for how a result gets used. A first-tier test that comes back negative is treated with more confidence than a second-tier one, which is part of why a positive Cologuard result cannot simply be watched — it moves straight to colonoscopy rather than to a repeat stool test.

How Accurate Is It, Briefly

The current version of Cologuard detects colorectal cancer with high sensitivity in the trial that supports it, alongside a lower specificity than colonoscopy — meaning it flags some people who do not actually have cancer or an advanced polyp 1. FIT alone, the blood-only test, has a pooled sensitivity of about 0.79 and a specificity of about 0.94 for colorectal cancer across independent studies 4, which is moderately sensitive and more specific than the combined DNA-and-blood test tends to be.

fit vs cologuard comparisons come down to that trade: FIT is simpler, cheaper, and repeated yearly, while the combined test gives up some specificity for a higher chance of catching an early cancer on a single round. how well cologuard actually catches cancer walks through the trial data in more depth than a mechanism page needs to.

Who It's For, and Whether Insurance Covers It

Cologuard is built for adults at average risk who have no symptoms — the same population the USPSTF recommends begin colorectal cancer screening at age 45, with a range of tests to choose among 5. Someone with rectal bleeding, a strong family history, or a prior polyp is generally not who this test was designed for; that person usually needs colonoscopy directly, on a different timeline than routine screening.

does insurance cover cologuard is a fair question to ask before ordering a kit, and federal law leans in the patient's favor. The ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal cancer screening with no cost-sharing, and if Cologuard comes back positive, the follow-up colonoscopy is billed and covered as screening rather than as a new diagnostic problem 6. Medicaid coverage varies by state, which is worth confirming directly. cologuard cost as a cash-pay question, and the fuller list-price picture, belong to their own page — this one is about what the test is doing, not what it charges.

Common questions

No. A positive result means the DNA or blood signal crossed the test's threshold — it does not say what caused that, whether a polyp, an early cancer, or something else. Only a colonoscopy can look directly and find out. Most positive stool tests do not turn out to be cancer, but the only way to know is the follow-up procedure, not another round of the stool test.

FIT checks a stool sample for one thing: hemoglobin, the protein in blood. Cologuard checks for that plus altered DNA shed by colon cells, combining both readings into one result. That combination generally makes it more likely to flag an early cancer on a single test, at the cost of flagging more people who do not actually have one.

The kit is designed for home use: no laxative prep, no clinic visit, no special diet beforehand. A whole bowel movement goes into the provided container, a small portion transfers to a preservative vial, and the sealed kit mails back in the box provided. Following the kit's own instructions exactly matters more than anything else in the process.

Neither claim is quite right. Guideline groups generally rank colonoscopy and annual FIT above the stool DNA test, placing Cologuard as a second-tier option — a reasonable choice for someone who would not otherwise get screened, not necessarily the top pick on performance alone.

For adults in the recommended screening age range, generally yes — the ACA requires no-cost coverage for USPSTF-recommended colorectal cancer screening, and that includes stool-DNA testing. If the result comes back positive, the follow-up colonoscopy is also billed as screening rather than as a new problem, though Medicaid rules vary by state.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to skip the stool test and call your clinician instead

  • —Rectal bleeding, blood in the stool, or a new change in bowel habits — these need evaluation now, not a routine screening test
  • —A first-degree relative diagnosed with colorectal cancer or an advanced polyp, especially before age 50 — screening usually needs to start earlier and with a different test
  • —Unintentional weight loss, persistent abdominal pain, or a known iron-deficiency anemia alongside a plan to order a stool test

This page explains what Cologuard measures and how to read a result. It is educational, not a screening recommendation for any individual, and it does not replace a conversation with a clinician about which test and which schedule fit your own risk.

References

  1. 1.Imperiale TF, Porter K, Zella J, et al. (BLUE-C Study Investigators) (2024). Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. New England Journal of Medicine. doi:10.1056/NEJMoa2310336 ✓That the BLUE-C trial validated the current-generation multitarget stool DNA test, reporting its sensitivity for colorectal cancer and its specificity in an average-risk screening population — used to describe the combined DNA-and-blood mechanism and the trial behind today's version of the test.
  2. 2.Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. (2014). Multitarget stool DNA testing for colorectal-cancer screening. New England Journal of Medicine. PMID 24645800 ✓That the pivotal study behind FDA approval of the first-generation Cologuard test found multitarget stool DNA testing had higher single-test sensitivity for colorectal cancer than FIT but lower specificity — used to explain the historical basis and the sensitivity/specificity trade-off of the test.
  3. 3.Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017). Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy. doi:10.1016/j.gie.2017.04.003 ✓That the Multi-Society Task Force ranks colonoscopy every ten years and annual FIT as first-tier screening options, with mt-sDNA (Cologuard) and CT colonography as second-tier — used to place Cologuard within the broader screening menu.
  4. 4.Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014). Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Annals of Internal Medicine. doi:10.7326/M13-1484 ✓That FIT has pooled sensitivity of about 0.79 and specificity of about 0.94 for colorectal cancer — used to contrast the blood-only test's accuracy profile with the combined DNA-and-blood test.
  5. 5.U.S. Preventive Services Task Force (USPSTF) (2021). Colorectal Cancer: Screening (Final Recommendation). U.S. Preventive Services Task Force. link ✓That the USPSTF recommends average-risk colorectal cancer screening begin at age 45 — used to define the intended population for Cologuard.
  6. 6.American Cancer Society (2024). Insurance Coverage for Colorectal Cancer Screening. American Cancer Society (cancer.org). link ✓That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal cancer screening with no patient cost-sharing, and that a follow-up colonoscopy after a positive stool test is covered as screening rather than billed as a new diagnostic problem; Medicaid coverage varies by state.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library